Compared with placebo, semaglutide was associated with improved quality of life outcomes for patients with type 2 diabetes and chronic kidney disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results